GLOBALHealthPR
VIVA! continues winning streak at PRIA annual NSW Awards for Excellence
VIVA! Communications attended the Public Relations Institute of Australia (PRIA) annual 2018 NSW Awards for Excellence last night, held at The Rawson Room in The Rocks, Sydney. It was a great night attended by our NSW industry peers. We entered three separate submissions into the NSW Awards and were delighted to clinch two wins and…
Read MoreWorldwide recognition for GLOBALHealthPR partners
The past few weeks have seen our GLOBALHealthPR partners receiving worldwide recognition for their fantastic work in Health + Wellness PR. Last week, our agency, VIVA! Communications, was thrilled to clinch Australia’s ‘Best Public Health Initiative’ at the pharmaceutical industry’s annual PRIME Awards for our Enhancing Community Immunity Through Pharmacist-led Flu Vaccination campaign in partnership with…
Read MoreGLOBALHealthPR appoints VIVA! Communications ‘Asia-Pacific hub’ & welcomes Spurwing Communications as exclusive Singaporean partner
GLOBALHealthPR, the world’s largest partnership of independent health and science communications agencies, today appointed longstanding Australian partner, VIVA! Communications, ‘regional hub’ for Asia-Pacific. The strategic partnership also welcomed Singapore-based Spurwing Communications to its network today, further strengthening GLOBALHealthPR’s capabilities in the Asia-Pacific (APAC) region. Having earned an enviable reputation for servicing the local, regional and…
Read MoreFundraising success for the RSPCA as Dogust draws to a close
As GLOBALHealthPR (GHPR) initiative #Dogust draws to conclusion, VIVA! Communications is celebrating the roaring success of our recent fundraising bake sale for the RSPCA. Generating more than $170 through in-person donations alone, VIVA! raised the dough this year by 34 per cent in comparison to the same event last year. Celebrating ‘Cupcake Day’, an annual…
Read MoreFirst-Ever Therapy to Demonstrate Survival Benefit in Progeria
A new study published in The Journal of the American Medical Association (JAMA) reports that lonafarnib, a farnesyltransferase inhibitor (FTI), helped extend survival in children with Hutchinson-Gilford Progeria Syndrome (HGPS), or Progeria, an ultra-rare and fatal disease that causes premature aging in children. Children with Progeria live an average 14 ½ years, dying from heart…
Read More